ASCO, Clinical Trials for Life
A look at the clinical trials side of oncology.
As I write this, it is three days before the ASCO Annual Meeting, the first in a series of conferences that arrive in rapid succession, such as CMSC, ASMS, ACR, and the many more conferences that the healthcare brands under MJH Life Sciences® cover. For the Applied Clinical Trials’ audience, we also look forward to attending the Drug Information Association (DIA) Global Annual Meeting at the end of June in Boston.
However, it is ASCO that holds a special place at the heart of MJH. Our flagship iconic oncology brands include OncLive®, Targeted Oncology™, CancerNetwork®, and CURE®. We also offer academic and community oncologists, nurses, patients, and all involved with the cancer care journey with an unmatched selection of resources. These include our live educational events, along with digital and print solutions that deliver the peer-to-peer education needed for improving patient outcomes. From video editorials to conference coverage, we independently produce content that combines objective facts and expert insights for the cancer care community.
While Applied Clinical Trials’ mission isn’t to report the clinical trial results, it is the results from the actual conduct of these oncology clinical trials that are reported. Where would oncology trials be without a team of investigators, clinical research coordinators, data managers, lab providers, medical writers, and many more? That is where Applied Clinical Trials comes in, on the operations side of drug development.
Clinical trials represent the research side of the clinical care continuum in oncology. Of all the therapies in development, oncology is the largest in the pipeline. That is representative of the true need for cancer treatments. While many patients can participate in clinical trials, many more do not or are not given access due to lack of knowledge or overly strict exclusion criteria.
On both sides of our business—healthcare and industry sciences—we continuously hear about those who have entered the field of oncology in a variety of roles to make an impact on those suffering from cancer. Whether it is an investigator, a pharma CEO, CRO project manager, or clinical research nurse, many are on the front lines with their stories that touch a tremendous amount of people with their compassion. We would like to thank them all for bringing us one step closer to a world without cancer.
Thank you for reading.
Mike Hennessy Jr., president and CEO, MJH Life Sciences®
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
